Loading...
Market
Will BioNTech face new COVID-19 vaccine royalty lawsuits by the end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Court records or official announcements from BioNTech
Story
BioNTech Settles COVID-19 Vaccine Royalties, Paying $791.5M to NIH and $467M to UPenn
Dec 27, 2024, 02:00 PM
BioNTech has reached two separate settlement agreements concerning royalty payments related to its COVID-19 vaccine. The company will pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania. These agreements were confirmed by BioNTech in recent filings. The settlements address disputes over whether royalties were owed based on the locations where the licensed products were manufactured and sold. Despite these settlements, BioNTech will retain license rights under certain patents held by the University of Pennsylvania.
View original story
Similar markets
Yes • 50%
No • 50%
Overturned • 25%
Other • 25%
Upheld • 25%
Settled • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
No • 50%
Yes • 50%
Decreased trust in mRNA vaccines • 25%
Increased trust in mRNA vaccines • 25%
Mixed opinions • 25%
Trust remains unchanged • 25%